Durect Corporation Asset Resilience Ratio
Durect Corporation asset resilience ratio. Durect Corporation (DRRX) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DRRX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Durect Corporation (1999–2024)
Asset resilience ratio of Durect Corporation from 1999 to 2024. This chart shows how Durect Corporation's Asset Resilience Ratio has changed over time. Read DRRX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Durect Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Durect Corporation assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Durect Corporation maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Durect Corporation Industry Peers by Asset Resilience Ratio
Compare Durect Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Durect Corporation Asset Resilience Ratio by Year (1999–2024)
Durect Corporation asset resilience ratio by year from 1999 to 2024. The table below shows the annual Asset Resilience Ratio data for Durect Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.32% | $792.00K | $18.35 Million | +1.48pp |
| 2023-12-31 | 2.83% | $1.28 Million | $45.19 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $60.10 Million | -- |
| 2021-12-31 | 21.70% | $19.97 Million | $91.99 Million | -3.97pp |
| 2020-12-31 | 25.68% | $19.42 Million | $75.64 Million | -8.91pp |
| 2019-12-31 | 34.58% | $29.75 Million | $86.02 Million | +29.24pp |
| 2018-12-31 | 5.34% | $2.67 Million | $50.00 Million | -8.56pp |
| 2017-12-31 | 13.90% | $7.38 Million | $53.11 Million | -34.48pp |
| 2016-12-31 | 48.39% | $19.60 Million | $40.51 Million | -6.04pp |
| 2015-12-31 | 54.43% | $25.46 Million | $46.77 Million | -5.50pp |
| 2014-12-31 | 59.93% | $30.02 Million | $50.08 Million | +28.69pp |
| 2013-12-31 | 31.24% | $12.75 Million | $40.82 Million | -6.50pp |
| 2012-12-31 | 37.74% | $17.34 Million | $45.94 Million | -2.71pp |
| 2011-12-31 | 40.45% | $19.90 Million | $49.20 Million | -11.46pp |
| 2010-12-31 | 51.91% | $35.07 Million | $67.56 Million | -4.55pp |
| 2009-12-31 | 56.46% | $32.83 Million | $58.15 Million | +28.64pp |
| 2008-12-31 | 27.83% | $20.84 Million | $74.87 Million | +4.37pp |
| 2007-12-31 | 23.46% | $19.71 Million | $84.02 Million | -4.15pp |
| 2006-12-31 | 27.61% | $28.30 Million | $102.48 Million | +12.26pp |
| 2005-12-31 | 15.35% | $18.02 Million | $117.41 Million | -10.12pp |
| 2004-12-31 | 25.47% | $21.77 Million | $85.47 Million | -9.68pp |
| 2003-12-31 | 35.15% | $39.51 Million | $112.41 Million | -4.20pp |
| 2002-12-31 | 39.35% | $28.71 Million | $72.97 Million | -1.26pp |
| 2001-12-31 | 40.60% | $42.61 Million | $104.94 Million | -7.26pp |
| 2000-12-31 | 47.86% | $57.73 Million | $120.61 Million | -8.83pp |
| 1999-12-31 | 56.69% | $12.73 Million | $22.46 Million | -- |
About Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more